Candel
Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial
Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval
Actionable Insights Powered by AI
Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval